Sunday , October 17 2021

Cipla rises on launching Daptomycin for Injection

Cipla is currently trading at Rs. 435.00, up by 0.55 points or 0.13% from its previous closing of Rs. 434.45 on the BSE.

The scrip opened at Rs. 440.00 and has touched a high and low of Rs. 440.00 and Rs. 434.40 respectively. So far 15545 shares were traded on the counter.

The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 677.45 on 27-Sep-2018 and a 52 week low of Rs. 432.00 on 25-Sep-2019.

Last one week high and low of the scrip stood at Rs. 472.15 and Rs. 432.00 respectively. The current market cap of the company is Rs. 35020.04 crore.

The promoters holding in the company stood at 36.70%, while Institutions and Non-Institutions held 41.84% and 21.46% respectively.

Cipla has launched Daptomycin for Injection, 500mg/vial, single-dose vial (for intravenous use only), AP-rated generic equivalent of Cubicin for Injection in the United States. According to IQVIA (IMS Health), Cubicin for Injection (daptomycin for injection) had US sales of approximately $606 Million for the 12-month period ending June 2019.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients. The company’s portfolio includes over 1500 products across wide range of therapeutic categories with one quality standard globally.

Please share this news
<div id="taboola-below-article-thumbnails"></div>
<script type="text/javascript">
  window._taboola = window._taboola || [];
    mode: 'thumbnails-a',
    container: 'taboola-below-article-thumbnails',
    placement: 'Below Article Thumbnails',
    target_type: 'mix'